Vericel Corporation's Upcoming Financial Reporting
Cambridge, Massachusetts - Vericel Corporation (NASDAQ:VCEL), a prominent name in advanced therapies aimed at sports medicine and severe burn management, has announced an engaging event for investors and stakeholders. The company will reveal its financial results for the third quarter of 2024 on Thursday, November 7, 2024. This financial disclosure is vital for those following the trajectory of the company, as it underlines their commitment to transparency and growth.
Listening to the Conference Call
Vericel's management team is set to host a conference call alongside a live webcast starting at 8:30 a.m. (ET). During this session, they will delve into the financial data and shed light on the key business developments that shaped the quarter. This initiative not only reflects Vericel's dedication to engaging with its investors but also provides a platform for stakeholders to gain deeper insights into the company's operations and future outlook.
Accessing the Webcast
The live webcast of this significant event can be accessed through the Investor Relations section of the Vericel website. Participants are encouraged to join at least 15 minutes early to ensure they have sufficient time to download necessary audio software. Presentation slides that accompany the conference call will also be available during the broadcast.
About Vericel Corporation
Vericel has established itself as a leading provider of innovative therapies tailored for the sports medicine and severe burn care markets. By merging advanced biology with cutting-edge medical technologies, Vericel delivers a unique range of cell therapies and specialty biologics designed to heal injuries and enhance the quality of life for patients. This commitment to innovation is showcased through their three marketed products within the United States.
Innovative Product Portfolio
The company's flagship offerings include MACI and Epicel, both of which play critical roles in patient recovery. MACI, or autologous cultured chondrocytes on porcine collagen membrane, is designed to address full-thickness cartilage defects in adults, making it a crucial option for those facing knee-related issues. Conversely, Epicel, known as cultured epidermal autografts, serves as a permanent solution for patients suffering from extensive burns, notably those involving significant body surface area.
Exclusive Licensing of NexoBrid
Vericel also proudly holds exclusive North American rights to NexoBrid, a groundbreaking biological product that aids in eschar removal for patients with deep partial-thickness and full-thickness burns. This demonstrates Vericel's ongoing commitment to providing comprehensive care solutions for patients with severe injuries.
Investor and Media Relations
For more information regarding the upcoming financial results and to stay updated on the company's advancements, stakeholders can connect with the investor relations team. Eric Burns, the dedicated Investor Contact, is available at ir@vcel.com or by phone at +1 (734) 418-4411. Furthermore, media inquiries can be directed to Julie Downs via media@vcel.com.
Frequently Asked Questions
What date will Vericel release its Q3 2024 financial results?
Vericel will report its financial results on November 7, 2024.
How can I access the conference call?
The conference call can be accessed via the Investor Relations section of the Vericel website, starting at 8:30 a.m. (ET).
What products does Vericel offer?
Vericel markets several products including MACI, Epicel, and NexoBrid, focusing on sports medicine and burn care.
Who can I contact for investor relations?
For investor relations inquiries, you can contact Eric Burns at ir@vcel.com.
What is the significance of the results announcement?
The financial results announcement provides stakeholders with insights into the company's performance and future strategies in the therapeutic market.
